According to the latest Securities and Exchange Commission (SEC) filing, Brighton Jones LLC has raised its stake in Neurocrine Biosciences, Inc. (Nasdaq: NBIX) by 266.2% in the third quarter. Brighton Jones LLC acquired 7426 shares in the quarter. They hold 10,216 shares worth approximately $1,434,000. In addition to Brighton Jones LLC, Allspring Global Investments Holdings LLC, and Assetmark Inc. are the other two major institutional investors who increased their stake in Neurocrine Biosciences in the same quarter.
Neuroscience-focused, biopharmaceutical major, NBIX closed at 147.28, shedding 0.17%. One of the key reasons for the downtrend is attributed to the disappointing results of the Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy. The study found that valbenazine did not work as hoped, as it failed to improve involuntary movements (chorea) in children and adults with dyskinetic cerebral palsy, even though the drug was safe and well-tolerated.
Commenting on the study, Sanjay Keswani, M.D., Chief Medical Officer, Neurocrine Biosciences, stated, “These results are disappointing, as there are no approved treatments for people living with dyskinetic cerebral palsy.” He further added, “We are deeply grateful to the patients and their families, as well as the investigators and site staff, whose commitment, dedication, and participation made this clinical trial possible.”
The study is the largest controlled clinical trial ever done in dyskinetic cerebral palsy. The study tested 14 weeks of valbenazine versus a placebo in children and adults with involuntary movements. Cerebral palsy (CP) is a nonprogressive neurodevelopmental disorder that affects three per 1,000 children in the United States.
Analysts’ Rates ‘Strong Buy’ For Neurocrine Biosciences, Inc. $NBIX
Analysts from HC Wainwright & Co. and Stifel maintain a ‘Strong Buy’ with 34.44% and 27.65% upside. While the analyst from Mizuho is keeping the ‘Hold’ rating. The average stock rating remains as ‘Strong Buy’.
The company has recorded strong numbers in the latest earnings report. According to the report, the company recorded a GAAP net income of $210 million and $2.04 earnings per share in the third quarter, which is higher than the figures reported in the third quarter of the previous year. The NBIX stock price fluctuated in the range of 84.23 to 160.18. Historic data show the stock gained in the last 3 quarters.
| Date | Open | High | Low | Close | Adj. Close | Change | Volume |
| Q4 2025 | 140.12 | 160.18 | 133.61 | 147.28 | 147.28 | 4.92% | 59,690,909 |
| Q3 2025 | 126.2 | 148 | 123.67 | 140.38 | 140.38 | 11.69% | 56,389,323 |
| Q2 2025 | 110.59 | 130.46 | 84.23 | 125.69 | 125.69 | 13.64% | 88,266,334 |
| Q1 2025 | 137.07 | 154.61 | 105.18 | 110.6 | 110.6 | -18.97% | 78,117,326 |
Yet, the risks associated with the company include drug trial failures, heavy reliance on one main product, regulatory delays, strong competition, high R&D costs, and price swings common in biotech stocks
